HONG KONG SAR – Media OutReach
– 26 April 2023 – A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases – SinoMab BioScience Limited (Stock Code: 3681.HK, “SinoMab” or the “Company”)
, is pleased to announce that Phase III clinical trial of SinoMab’s flagship product SM03 (Suciraslimab) for rheumatoid arthritis (RA) in China (Study No.: SM03-RA-III) has completed unblinding and initial statistical analysis and achieved the primary endpoint, marking a significant step towards Suciraslimab’s commercial launch.
Suciraslimab is a global first-in-target anti-CD22 monoclonal antibody for the treatment of rheumatoid arthritis, and it is also the first-in-class anti-CD22 naked monoclonal antibody that has completed phase III clinical trial and reached the primary endpoint. The Phase III clinical trial is a randomized, multi-centre, double-blind, placebo-controlled study to confirm the clinical efficacy and safety in patients with moderate-to-severe active RA who had an inadequate response to methotrexate (MTX). The primary endpoint of the phase III trial is to measure the percentage of participants with ACR 20 response at week 24. ACR20 is a composite measure for the assessment of rheumatoid arthritis improvement by the American College of Rheumatology, defined as a minimum 20% improvement in the number of tender and number of swollen joints compared to the patient’s own baseline, and at least 20% improvement in three of the following five measurements: including three visual scoring scale (VAS, which refers to doctors’ overall assessment of disease activity, patients’ general assessment of disease activity, patients’ assessment of pain conditions), the patient’s health assessment questionnaire (HAQ-DI) and the level of acute phase reactant (blood sediment or C-reaction protein) tested by laboratories.
The Phase III study results showed that Suciraslimab was effective in suppressing disease activity and alleviating symptoms of active RA patients receiving MTX therapy. Relevant study result shall be published in academic journals and academic conferences.
As a self-developed global first-in-target and first-in-class product of the Company, Suciraslimab demonstrates clinical efficacy for the treatment of RA and via the modulation of B cell activity, it has the potential for the treatment of other immunological diseases. By adopting a novel mechanism of action, which differentiates itself from the current treatments available in the market, Suciraslimab offers a new option for RA patients to obtain long-term treatment benefits, addressing the limitations of currently available treatments in terms of efficacy, safety, and in particular, deficiency in long-term post-drug resistance against mature RA targets. Currently, the overall scale of existing patients with autoimmune diseases in China is huge. According to “Rheumatoid Arthritis in China: A National Report of 2020” issued by the National Clinical Research Center for Dermatologic and Immunologic Diseases in October 2021, there are about 5 million RA patients in China. According to Frost & Sullivan, the RA therapeutics market in the PRC is expected to reach RMB28 billion by 2023 and RMB83.3 billion by 2030. The unmet medical needs of RA patients in China are huge, and the market size of RA is also in a high-speed expansion stage. SinoMab is expected to fully share the benefits of the rapid development of the domestic autoimmune market.
SinoMab has been focusing on the R&D of monoclonal antibody drugs in the field of autoimmune diseases for more than 20 years, with an existing product pipeline covering a plethora of immunological disorders. SinoMab is one of the few biopharmaceutical companies in China that has the ability to integrate R&D, production, and commercialization to realize the entire industrial chain. The significant progress achieved in the Phase III clinical trial marks another big step towards the commercialization of Suciraslimab. The Group will accelerate the commercialization of Suciraslimab and strive to submit the Biologics License Application (BLA) to the National Medical Products Administration (NMPA) in the third quarter of 2023 at its earliest, so as to achieve commercialization subsequently and consolidate the first-mover advantage in the first-in-target and first-in-class of new medicine. While bringing the gospel to RA patients as soon as possible, we will promote the Company’s business development to a new level, and continue to move forward to the goal of becoming a leading global biopharmaceutical company for the development of novel drugs to fulfil unmet medical needs.
In addition to its flagship product, Suciraslimab, another of the Company’s core products, SM17, has made satisfactory progresses. SM17 is a humanised anti-IL-17RB monoclonal antibody, a First-in-Class and First-in-Target therapeutic product with potentials for treating diseases of type 2 immune responses such as asthma, atopic dermatitis, and idiopathic pulmonary fibrosis. Preclinical studies had revealed that SM17 is able to control inflammatory airway diseases such as asthma at a relatively early stage and is expected to address an unmet medical need by benefiting a large number of patients with severe uncontrolled asthma. The first IND application for the treatment of asthma was approved by the U.S. Food and Drug Administration (“FDA”) in March 2022 and the first healthy subject had been successfully dosed in a Phase I First-in-Human (FIH) clinical study in the U.S. in June 2022. As of 31 December 2022, 59 subjects were enrolled and no serious adverse events were reported. We plan to carry out a bridging study in China and file an IND application for the treatment of asthma in China with the Center for Drug Evaluation (CDE) of NMPA in the first half of this year. Dr. Shui On LEUNG, Executive Director, Chairman and Chief Executive Officer of SinoMab
said that, “the market for therapeutics for autoimmune diseases is in a stage of rapid growth, in which the demand for rheumatoid arthritis treatment is high. However, there are limitations on the efficacy and safety of currently available drugs for RA treatment. Suciraslimab, the Company’s flagship product, is the world’s first CD22-targeted new drug that is expected to be approved for marketing for the treatment of rheumatoid arthritis. The Phase III clinical data readout has successfully reached the primary endpoint and further demonstrated the efficacy of the new drug. We would like to express our sincere gratitude to all researchers and subjects for their efforts in the smooth advancement of the clinical research of this project. As the first Hong Kong-based listed biopharmaceutical company, we are pleased Suciraslimab is destined to be our first drug to be commercially marketed. In the future, the Company will continue to make every effort to promote discovery research to identify novel targets and antibodies that address immunological diseases of unmet medical needs. The company will continue to strive to advance preclinical and clinical research for marketing approval, and achieve the goal of product commercialization in the shortest possible time. Realizing SinoMab’s commitments to becoming a leader in the innovation of novel drugs to fulfill unmet medical needs while creating more value returns for the Company and its shareholders is of prime importance.”
The issuer is solely responsible for the content of this announcement.
About SinoMab BioScience Limited
SinoMab BioScience Limited is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The R&D headquarters is located in Hong Kong and the production base is located in mainland China. The Company’s flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and has completed the Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), Alzheimer’s disease, systemic lupus erythematosus (SLE), pemphigus (PV), multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), non-Hodgkin’s lymphoma (NHL), asthma, and other diseases with major unmet clinical needs.
Stakeholder mapping, analysis, engagement and communication needs to be detailed to avoid business losses or even worse, a crisis. How can you do this effectively to prevent failure? ...
Data-driven business decisions have never been as crucial, especially in this era. MGBF leverages off, technology, experience and market presence to aid businesses in making accurate decisions. ...
MGBF provides comprehensive strategic advice and results-focused solutions to solve clients' problems in business-government relations so they can focus on their core business. ...
A critical business challenge is meeting the right decision-makers and potential buyers through the best channel and platform. How will you improve your business competency? ...
MGBF is hosting a networking session with Romania's global analyst, Radu Magdin, in Kuala Lumpur. Join the discussion on strategic shifts and conflict flash points that impact Malaysia’s international facing business.
Expanding on the Malaysian government's efforts to promote the country as a trade and investment destination of choice, MGBF will engage with the many industry leaders who announced multi-billion dollar commitments.
The global trend towards a sustainable future is driven by multiple forces. What does Malaysia have to do to achieve resilience at the corporate level while creating new business opportunities?
Special session: Cyberwarfare Waged on the Corporate Sector - Lessons from the Russia-Ukraine Crisis. Corporations are in a digital arms race that many don't realise. How does this relate to your organisation?
MGBF In The News
The classic knee-jerk reaction is to say, fire the coach, change the leadership of associations, and reduce the funding till they start performing better. This kind of negative reinforcement may work for kindergarten children, but we are dealing with high-performance adults – individuals much further along in their psychological and […]
Since its earliest tea plantations in 1929, Cameron Highlands has grown to become a key player in the agricultural landscape of Malaysia, producing 40 per cent of all vegetables grown. Despite Malaysia shifting its economic focus away from agriculture, the industry remains imperative for food security and the livelihoods of […]
Although at first glance the travel industry and the agricultural sector appear to have nothing in common, they actually share more than meets the eye. The economic benefits of tourism to the agricultural sector can be multiplied several times over. “Tourism brings the end consumers closer to the source, which […]
The Malaysia Global Business Forum (MGBF) recently held a high-level roundtable themed ‘Designing the Future of the Digital Economy’, attended by industry leaders and business associations. The guest of honour was Yang Berhormat Syerleena Abdul Rashid, the Member of Parliament (MP) for Bukit Bendera in Penang. The MP’s Special Session […]
The Malaysia Global Business Forum (MGBF) will be hosting a roundtable on ‘Designing the Future of the Digital Economy’ on 23 February 2023. It is the culmination of the first three MGBF Exclusive Roundtable Series titled ‘The Evolving Threat Matrix in the Digital Economy’ held throughout 2022. According to the […]
The Founding Chairman of the Malaysia Global Business Forum (MGBF), Nordin Abdullah, today spoke on Bernama TV’s leading English talk show, The Brief, hosted by Jessy Chahal, on the topic of a stable political reality and what that means for the Malaysian economy. Nordin said, “The first thing that it […]
More than 1,100 years ago, Muhammad ibn Musa al-Khwarizmi was developing the mathematical formulas that we know today as algorithms which now have become so intertwined with the business fortunes of global media giants and the very fabric of geopolitics. A series of recent high level international reports have revealed […]
KSK Land has been recognised by the Malaysia Global Business Forum (MGBF) for its role in attracting high net-worth individuals to Malaysia post-pandemic. The first challenge in investor attraction is “selling” the country. In the context of Asia, Malaysia is competing with some very established investment destinations. The second […]
Malaysia, in particular Kuala Lumpur, continues to position itself as a regional centre to do business, educate a family and enjoy a global lifestyle. One company, KSK Land, has taken the lead in positioning itself and the city of Kuala Lumpur as a property investment destination for the global citizen […]
The upcoming budget represents an opportunity to build resilience in the critical sectors that will form the backbone of the country’s future-facing economic ambitions. This however needs to be achieved in the context of managing the community sectors most impacted by COVID-19 over the past two years. The Keluarga Malaysia (Malaysian Family) […]
Malaysia Global Business Forum (MGBF) has moved to support the creative economy as the overall economy moves into a recovery phase following the COVID19 pandemic. As a step in the direction of normalcy, the MGBF has agreed to host the art exhibition “I Know You’re Somewhere So Far” by one […]
Congratulations to Datuk Seri Ismail Sabri Yaakob for taking up the mantle of the ninth prime minister of Malaysia. There is nothing normal about the situation; it could not have been scripted but it has kept the spectrum of media, mainstream and social, gripped. The first order of business for […]
In a stirring speech to the nation, President Joseph R. Biden, Jr. stamped his brand of leadership on the presidency, in his first act as the 46th president of the United State of America, it signaled several shifts. Perhaps the weather was foreboding with snow falling before the ceremony that […]
KUALA LUMPUR, 6 July 2022 – As the global economy continues to deal with unprecedented levels of disruption caused by the pandemic and the conflict between Russia and Ukraine, the convergence of energy security and food security issues has become a front-of-mind issue faced by policy makers and consumers alike. […]
KUALA LUMPUR, 23 June 2022 — Malaysia Global Business Forum (MGBF) ties up with scoutAsia to ensure that businesses are equipped with deeper regional insights. The past two years has seen a massive shift in the way businesses are conducted with digitisation, digitalisation and automation continuously being adopted to improve […]
KUALA LUMPUR, 25 May 2022 – The Malaysia Global Business Forum (MGBF)’s exclusive roundtable on ‘Security Concerns in Critical Value Chains’ was held in a hybrid setting yesterday at the Eastin Hotel Kuala Lumpur. The guest of honour was Yang Berbahagia Tan Sri Dato’ Seri Rafidah Aziz, former minister of […]
We live in the age of crisis. At the heart of any crisis is the threat of rapid change. Change too deep or too wide that the current coping mechanisms for an individual, corporation or government are unable to remain resilient. An unwelcome paradigm shift, like the proverbial spider, that […]
The Malaysia Global Business Forum (MGBF) has released a report following the roundtable on ‘Digital Resilience in the Corporate Sector’, which was recently held in Kuala Lumpur. In attendance as guest of honour was Deputy Minister of Communications and Multimedia, Datuk Zahidi Zainul Abidin. The report recommended several critical development […]
Trade and investment delegations will trickle back over the next few months, but the second half of the year should see considerable return of business travellers. It was learnt that over 50 per cent of international business chambers and industry associations surveyed will consider sending exploratory teams to Malaysia during […]